Across TCGA pan-cancer cohorts, DDO Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DDO data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DDO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDO expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, LUSC, and SKCM are the cancer types where DDO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.156	0.726	.002	36	view →
LUSC	OS	Median	All	0.138	0.818	.003	6	view →
SKCM	DFS	Median	III,IV	0.918	0.597	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: DDO tumor-vs-normal RNA expression · all DDO data types